argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-09-19 09:49 | English | 441.3 KB | |||
| 2019-09-03 08:21 |
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference Se…
|
English | 29.3 KB | ||
| 2019-08-06 08:20 |
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference
|
English | 29.1 KB | ||
| 2019-08-01 09:03 |
argenx reports half year 2019 financial results and second quarter business upd…
|
English | 124.2 KB | ||
| 2019-07-25 09:14 |
argenx to report half year 2019 financial results and second quarter business u…
|
English | 35.8 KB | ||
| 2019-05-30 09:37 |
argenx to Present at Upcoming Investor Conferences
|
English | 31.5 KB | ||
| 2019-05-28 08:30 |
argenx announces publication of efgartigimod Phase 2 myasthenia gravis trial re…
|
English | 125.9 KB | ||
| 2019-05-22 08:32 |
argenx announces pipeline expansion and “argenx 2021” vision to build integrate…
|
English | 75.4 KB | ||
| 2019-05-15 14:29 |
argenx to Host R&D Day on May 22, 2019
|
English | 34.0 KB | ||
| 2019-05-09 08:43 |
argenx reports first quarter 2019 financial results and provide business update
|
English | 89.8 KB | ||
| 2019-05-08 09:27 |
argenx to Present at Bank of America Merrill Lynch 2019 Health Care Conference
|
English | 14.4 KB | ||
| 2019-05-07 16:12 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 34.3 KB | ||
| 2019-04-23 11:22 | English | 3.9 MB | |||
| 2019-03-26 08:26 |
argenx announces Annual General Meeting of Shareholders on May 7
|
English | 147.6 KB | ||
| 2019-03-14 08:33 |
argenx to receive first clinical milestone payment for product candidate develo…
|
English | 115.4 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
